Skip to main content

The U.S. House of Representatives recently passed the Hematological Cancer Research Investment and Education Act in conjunction with Blood Cancer Advocacy Day.

The Hematological Cancer Research Investment and Education Act will amend the Public Health Service Act to provide research, information and education about blood cancers. Blood cancers include leukemia, lymphoma and multiple myeloma. Collectively, these cancers are the fifth most commonly occurring cancers and the second leading cause of cancer death. Currently, there are approximately 700,000 individuals living with blood cancers in the United States. Each year, more than 100,000 Americans are diagnosed with blood cancer, with 60,000 annual deaths.

The Hematological Cancer Research Investment and Education Act resulted from the efforts of the Multiple Myeloma Research Foundation, the Blood Cancer Coalition, several senators and concerned citizens from around the country. The goal of the bill is to increase public understanding of the disease, as well as government commitment to research and treatment.

Copyright © 2018 CancerConnect. All Rights Reserved.

Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.